Modulight Biotherapeutics Raises $12.2M Seed to Advance Optogenetic Therapies for Neurological Disorders
Modulight Biotherapeutics, a Boston‑based biotech startup pioneering optogenetic neuromodulation therapies for severe neurological conditions, has raised $12.2 million in a Seed funding round to propel its platform toward clinical development. The financing will enable the company to advance preclinical programs, initiate IND‑enabling studies, expand manufacturing, and begin regulatory engagement with the U.S. Food and Drug Administration as it seeks to transform treatments for chronic pain, epilepsy, movement disorders and related neurological diseases.
The Seed round was led by Jibe Ventures and LocalGlobe, with additional participation from a syndicate of specialized biotechnology and early‑stage investors including Nexus Neurotech Ventures, RedSeed VC, Secret Chord Ventures, Fresh Fund, Saras Capital, SilverArc Capital and Sha’ar Mivnim. This broad consortium reflects investor confidence in Modulight’s scientific foundation and its novel approach to tackling neurological diseases that have long resisted safe and effective therapies.
Founded in 2022, Modulight builds on technology licensed from Yeda Research and Development, the commercial arm of the Weizmann Institute of Science, leveraging proprietary optogenetic tools to modulate specific neural circuits with light‑activated proteins. Rather than broadly altering brain function like traditional drugs or electrical stimulation, Modulight’s strategy focuses on precise, circuit‑level neuromodulation by using hypersensitive inhibitory opsins such as eOPN3 to rebalance dysfunctional neural activity. Early preclinical work has shown promising efficacy in animal models of chronic pain, epilepsy, and movement disorders such as Parkinson’s disease and essential tremor — findings that have helped attract investor interest and set the stage for clinical translation.
A key planned clinical application is for trigeminal neuropathic pain, a severe facial pain condition that is often debilitating and resistant to standard treatment. Because of the accessibility of the trigeminal nerve to minimally invasive light delivery methods, Modulight sees this indication as an ideal first step toward demonstrating the safety and effectiveness of its optogenetic platform in humans. The company is now preparing for pre‑IND discussions with the FDA and anticipates completing IND‑enabling studies by 2027, a major regulatory milestone that would allow human clinical trials to begin.
Modulight’s platform represents a potential paradigm shift in neuromodulation and neurological therapeutics. By encoding light‑sensitive proteins into target neurons and then using externally delivered light to modulate their activity precisely, the approach aims to target pathological neural circuits without harming surrounding healthy tissue or altering unrelated brain regions. This specificity could ultimately lead to treatments that are both effective and free from many of the side effects associated with broad‑acting pharmaceuticals or invasive surgical procedures.
The recently raised capital is earmarked for accelerating preclinical development, expanding manufacturing capabilities, engaging in regulatory strategy and execution, and strengthening the company’s scientific and operational teams. Modulight’s leadership has emphasized that achieving early milestones such as IND submission and subsequent clinical proof of concept will be critical for the company to unlock future strategic partnerships, larger institutional investments, and potential collaborations with pharmaceutical and medical device companies.
Investor enthusiasm for Modulight reflects a broader interest in technologies at the intersection of neuroscience and precision medicine. Funds such as Nexus Neurotech Ventures focus on breakthrough tools that bridge engineering and biology to address unmet needs in brain health, and their involvement underscores the belief that optogenetics — long a powerful research tool — may now be on the cusp of clinical applicability. Likewise, early‑stage investors like RedSeed VC and Secret Chord Ventures bring experience in backing transformative biotech innovations at early stages, helping nascent companies mature their platforms toward commercialization.
As Modulight advances its optogenetic platform through preclinical and regulatory stages, the company aims to deliver new therapeutic options for millions of patients living with conditions that currently have limited or unsatisfactory treatments. With a strong scientific foundation, a seasoned investor syndicate, and a clear plan toward clinical validation, Modulight is positioning itself as a potential leader in the emerging field of precision neuromodulation therapy, offering hope for more effective, targeted, and safer treatments for debilitating brain disorders.
